Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus
ContextPeroxisome proliferator–activated receptors (PPARs) are nuclear transcription
factors that modulate gene expression. Therapeutic agents targeting 2 distinct families of
PPARs (α and γ) have been introduced in the United States. The first dual-PPAR agonist,
muraglitazar, was reviewed by a US Food and Drug Administration (FDA) advisory
committee on September 9, 2005, resulting in a vote of 8: 1 recommending approval for its
use in controlling blood glucose levels in patients with type 2 diabetes. ObjectiveTo evaluate …
factors that modulate gene expression. Therapeutic agents targeting 2 distinct families of
PPARs (α and γ) have been introduced in the United States. The first dual-PPAR agonist,
muraglitazar, was reviewed by a US Food and Drug Administration (FDA) advisory
committee on September 9, 2005, resulting in a vote of 8: 1 recommending approval for its
use in controlling blood glucose levels in patients with type 2 diabetes. ObjectiveTo evaluate …